The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.
A. O. Sartor
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
S. Oudard
Consultant or Advisory Role - Sanofi
Honoraria - Novartis; Pfizer; Roche; Sanofi
M. Ozguroglu
No relevant relationships to disclose
S. Hansen
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
J. H. Machiels
Consultant or Advisory Role - Boehringer Ingelheim; Genmab; Merck
Research Funding - Merck; Novartis
L. Shen
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
J. S. De Bono
Employment or Leadership Position - Astellas Pharma; AstraZeneca; Genentech; Johnson & Johnson; Merck; Pfizer; Roche; Sanofi ; Takeda
Consultant or Advisory Role - Astellas Pharma; AstraZeneca; Genentech; Johnson & Johnson; Merck; Pfizer; Roche; Sanofi ; Takeda
Honoraria - Astellas Pharma; AstraZeneca; Genentech; Johnson & Johnson; Merck; Pfizer; Roche; Sanofi ; Takeda
Research Funding - AstraZeneca